Miami, Florida – Global Stem Cells Group, a leading organization in the field of regenerative medicine, is pleased to announce the appointment of Dr. Salih Yildirim as the new President of the International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group. Dr. Yildirim previously held the position of Director of Overseas Operations at ISSCA.
Dr. Salih Yildirim brings a wealth of experience and expertise to his new role as President of ISSCA. Having previously served as the Director of Overseas Operations, Dr. Yildirim has demonstrated his exceptional leadership skills and strategic vision throughout his career. He has played a vital role in expanding ISSCA’s international presence and fostering collaborations with stakeholders worldwide.
In a statement regarding the appointment, Dr. Daeyong Kim, the former President of ISSCA, expressed his confidence in Dr. Yildirim’s ability to lead the organization. Dr. Kim stated, “I think you are the best leader and the most prepared to be the President of ISSCA. Therefore, I think you should be the head of ISSCA.” Dr. Kim will now transition to other support functions within ISSCA.
Benito Novas, head of Public Relations for ISSCA, expressed his admiration for Dr. Salih Yildirim’s professional qualities. Novas said, “I have known and worked with Dr. Salih for more than 10 years, and I am honored to have him as President within the company. During these years, he has proven to be an exceptional leader with a great vision for ISSCA.”
ISSCA’s objectives under the leadership of Dr. Salih Yildirim will include advancing the understanding and application of stem cell therapies, promoting scientific research and collaboration among professionals in the field, and advocating for the ethical and responsible use of regenerative medicine worldwide. Dr. Yildirim’s extensive experience in business development, international relations, and regenerative medicine will undoubtedly contribute to the achievement of these objectives.
About Dr. Salih Yildirim:
Dr. Salih Yildirim holds a bachelor’s and master’s degrees in business administration from Cleveland State University (United States) and a Ph.D. in health management from the University of Health Sciences. He has held various key positions throughout his career, including Director of Overseas Operations at ISSCA. Dr. Yildirim is currently the General Manager of BioTrend Medical International, a biotechnology firm specializing in genetics, molecular biology, and stem cell technologies. He also serves as the chief executive officer of ReGen.IC Clinic, specializing in regenerative medicine and stem cell applications. Additionally, he is a member of the International Society for Stem Cell Application’s Board of Directors and the Global Stem Cell Group’s Board of Directors and International Operations Manager. Dr. Yildirim is also a member of Istanbul Atlas University’s Board of Directors. He is married and a proud father.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
